Prashant Kumar: Medanta Cancer Congress – a great initiative with a goal to discuss Cell and Gene Therapy in the Era of Precision Medicine
Prashant Kumar, Chief Scientific Officer at Datar Cancer Genetics and Adjunct Professor at Indian Institute of Technology, shared a post on LinkedIn:
“Medanta Patna had organized an incredible MEDENTA Cancer Congress, Chapter 3, a great initiative which congregate clinicians, Scientists and Pharma with a goal to discuss Cell and Gene Therapy in the Era of Precision Medicine!
Kudos to Dr AMARENDRA AMAR and the full team of Medanta, Patna for hosting such a phenomenal meeting-bringing minds to advance the translational landscape of Cancer Therapy. I am proud to be part of this event and witness the momentum in bridging science to cure!
My presentation focused on “Central Dogma: Gene or Molecule or Something More”. It is important to understand the flow of Information from DNA to RNA to Proteins (Genetic instructions turned into functional outcomes in the cell). Also, how can we decode DNA to design better drugs? or Translate RNA to tailor Personalized Medicine.
The collation of the data would accelerate the development of targeted therapies, improve early diagnosis, and facilitate advance technology integration.
MultiOmics Integration could revolutionize medicine and hone our understanding about Cell Therapy by unraveling the biological complexity to create next-gen therapies which will be targetable, durable, and adaptable!!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023